The Complex Type 2 Endotype in Allergy and Asthma: From Laboratory to Bedside
The DOI matches its Crossref record; 76 of the 77 references it cites were found in a registry or an index.
Abstract
Better management of allergic diseases needs a sharpened understanding of disease heterogeneity and mechanisms in relation to clinically significant outcomes. Phenotypes describing observable clinical and morphologic characteristics and unique responses to treatment have been developed; however, they do not relate to disease mechanisms. Recently, extended heterogeneous and disease-related metabolic, inflammatory, immunological, and remodeling pathways have been described, and reproducible patterns are defined as disease endotypes. An endotype might consist of several intricated mechanisms that cannot be clearly separated into "pure single molecular mechanism" thus being a "complex endotype." The description of an endotype may rely on biomarkers, which can be the signature of a complex underlying pathway or a key molecule associated with or directly playing a role in a particular disease endotype. The Th2 type inflammation can be defined as a complex endotype in asthma and linked to mechanisms of disease development and response to treatment and to disease outcomes such as exacerbations and remodeling. The type 2 complex endotype in allergies and asthma includes innate lymphoid cells, T helper 2 cells, tissue eosinophilia, and IgE production. Currently, emerging endotype-driven strategies in asthma, particularly the development of biologicals that target a single molecular pathway, are being focused for solving individualized clinical problems on disease outcomes. Progress is also being made for endotyping rhinitis, chronic rhinosinusitis, and atopic dermatitis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In allergic diseases, the prominent endotype is type 2 (eg, Th2 cells, type 2 B-cells, IL-4-producing natural killer [NK]/T cells, basophils, eosinophils, mast cells, ILC2, IL-4, IL-5, IL-13, IL-25, IL-31, IL-33).319,341”
From International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (2018) · cites this paper as [341]
Citations
Cites
Pavord, I. D., Korn, S., Howarth, P., Bleecker, E. R., Buhl, R., Keene, O. N., Ortega, H., & Chanez, P. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60988-x · Cited by 2,221
T-helper Type 2–driven Inflammation Defines Major Subphenotypes of Asthma
Woodruff, P. G., Modrek, B., Choy, D. F., Jia, G., Abbas, A. R., Ellwanger, A., Arron, J. R., Koth, L. L., & Fahy, J. V. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200903-0392oc · Cited by 1,803
Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial
Green, R. H., Brightling, C. E., McKenna, S., Hargadon, B., Parker, D., Bradding, P., Wardlaw, A. J., & Pavord, I. D. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11679-5 · Cited by 1,755
Lebrikizumab Treatment in Adults with Asthma
Corren, J., Lemanske, R. F., Hanania, N. A., Korenblat, P. E., Parsey, M. V., Arron, J. R., Harris, J. M., Scheerens, H., Wu, L. C., Su, Z., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1106469 · Cited by 1,514
Mjösberg, J. M., Trifari, S., Crellin, N. K., Peters, C. P., van Drunen, C. M., Piet, B., Fokkens, W. J., Cupedo, T., & Spits, H. (2011) · Nature Immunology · doi:10.1038/ni.2104 · Cited by 1,166
Asthma endotypes: A new approach to classification of disease entities within the asthma syndrome
Lötvall, J., Akdis, C. A., Bacharier, L. B., Bjermer, L., Casale, T. B., Custovic, A., Lemanske, R. F., Wardlaw, A. J., Wenzel, S. E., & Greenberger, P. A. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.11.037 · Cited by 1,160
Hirai, H., Tanaka, K., Yoshie, O., Ogawa, K., Kenmotsu, K., Takamori, Y., Ichimasa, M., Sugamura, K., Nakamura, M., Takano, S., et al. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.2.255 · Cited by 1,099
Halim, T. Y. F., Steer, C. A., Mathä, L., Gold, M. J., Martinez-Gonzalez, I., McNagny, K. M., McKenzie, A. N. J., & Takei, F. (2014) · Immunity · doi:10.1016/j.immuni.2014.01.011 · Cited by 949
Innate and adaptive immune responses in asthma
Holgate, S. T. (2012) · Nature Medicine · doi:10.1038/nm.2731 · Cited by 902
Exploring the Effects of Omalizumab in Allergic Asthma: An Analysis of Biomarkers in the EXTRA Study
Hanania, N. A., Wenzel, S., Rosén, K., Hsieh, H.-J., Mosesova, S., Choy, D. F., Lal, P., Arron, J. R., Harris, J. M., & Busse, W. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201208-1414oc · Cited by 901
Research works printed but not linked: 1
- Akdis M, Akdis C. Immune tolerance. In: Bochner BS, Adkinson Jr NF, Burks W, Busse WW, Holgate Jr ST, Lemanski RF, O’Hehir RE, editors. Middleton’s allergy. 8th ed. Cambridge: Elsevier; 2013.
Cited by
Akdis, M., Aab, A., Altunbulakli, C., Azkur, K., Costa, R. A., Crameri, R., Duan, S., Eiwegger, T., Eljaszewicz, A., Ferstl, R., et al. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.06.033 · Cited by 912
Self-citationType 2 immunity in the skin and lungs
Akdis, C. A., Arkwright, P. D., Brüggen, M.-C., Busse, W., Gadina, M., Guttman‐Yassky, E., Kabashima, K., Mitamura, Y., Vian, L., Wu, J., et al. (2020) · Allergy · doi:10.1111/all.14318 · Cited by 560
International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis
Wise, S. K., Lin, S. Y., Toskala, E., Orlandi, R. R., Akdis, C. A., Alt, J. A., Azar, A., Baroody, F. M., Bachert, C., Canonica, G. W., et al. (2018) · International Forum of Allergy & Rhinology · doi:10.1002/alr.22073 · Cited by 557
International consensus statement on allergy and rhinology: Allergic rhinitis – 2023
Wise, S. K., Damask, C., Roland, L. T., Ebert, C., Levy, J. M., Lin, S., Luong, A., Rodriguez, K., Sedaghat, A. R., Toskala, E., et al. (2023) · International Forum of Allergy & Rhinology · doi:10.1002/alr.23090 · Cited by 507
Agache, I., & Akdis, C. A. (2019) · Journal of Clinical Investigation · doi:10.1172/jci124611 · Cited by 313
Self-citation
Metadata
- Authors
- Agache, I., Sugita, K., Morita, H., Akdis, M., & Akdis, C. A.
- Affiliations
- Transilvania University of Brașov (RO)
- University of Zurich (CH)
- Corresponding author
- Agache, Ioana
- Venue
- Current Allergy and Asthma Reports
- Published
- 2015-06
- Volume
- 15
- Issue
- 6
- Pages
- 29-29
- ISSN
- 1529-7322 (ISSN-L)
- 1534-6315
- OpenAlex
- W1192231709
- Cited by
- 86
- References
- 77
- Citations by year
- 2026: 4 · 2025: 3 · 2024: 1 · 2023: 3 · 2022: 7 · 2021: 4 · 2020: 13 · 2019: 8 · 2018: 13 · 2017: 10 · 2016: 14 · 2015: 5
- FWCI
- 1.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Current Allergy and Asthma Reports (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Health Sciences › Medicine › Immunology and Allergy › Allergic Rhinitis and Sensitization
- Life Sciences › Immunology and Microbiology › Immunology › IL-33, ST2, and ILC Pathways
- Keywords
- allergic diseases, asthma, allergy, type 2 inflammation, innate lymphoid cells, Th2 cells, tissue eosinophilia, IgE, airway remodeling, asthma exacerbations, biologic therapy, endotyping, rhinitis, chronic rhinosinusitis, atopic dermatitis, disease heterogeneity
- MeSH terms
- Asthma, Eosinophils, Humans, Hypersensitivity, Phenotype, Biomarkers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Complex Type 2 Endotype in Allergy and Asthma: From Laboratory to Bedside. https://app.cochat.ai/papers/10.1007/s11882-015-0529-x
- The paper
- Agache, I., Sugita, K., Morita, H., Akdis, M., & Akdis, C. A. (2015). The Complex Type 2 Endotype in Allergy and Asthma: From Laboratory to Bedside. Current Allergy and Asthma Reports. https://doi.org/10.1007/s11882-015-0529-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.